WIL Research Partners with Three S Japan
News May 24, 2013
WIL Research is partnering with Three S Japan, a company that provides support services in these industries, to represent its full portfolio of global safety assessment services in Japan.
WIL Research offers a blend of technical and regulatory expertise in discovery support, product safety toxicological research, metabolism, bioanalytical chemistry, analytical chemistry and formulation services.
They chose the Japan-based company to represent these services on the basis of its extensive network of clients, leadership experience with both pharmaceutical and chemical industry safety assessment, and its commitment to providing tailored, local client service.
“Three S Japan has a strong reputation serving the country’s pharmaceutical industry with high quality regulatory services underpinned by exceptional client focus,” said David Spaight, Chairman and CEO of WIL Research.
Spaight continued, “Through this partnership, clients will benefit from direct access to staff that can harness the full portfolio of WIL Research’s global services.”
CEO and President of Three S Japan, Koichi Hagita said, “WIL Research’s excellent reputation and our long-term client relationships and regulatory experience in the Japanese market will boost both our companies’ potential for growth.”
Three S Japan has operational centers in Tokyo and Osaka for pharmaceutical regulatory registration services.
The company provides toxicological support from pre-clinical to clinical development, and is experienced in the preparation, translation, and quality control checks of submission documents for New Drug Applications and Investigational New Drug applications.
Three S Japan also offers personalized consulting tailored to clients’ needs.
WIL Research was recently one of the winners of the CRO Leadership Award for Quality, awarded annually to leaders in quality, productivity, regulatory, accessibility, and reliability.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Synchrotron Light Shows Human Domestication of Seeds From 2000BCNews
For the first time, scientists from University College London have used the UK's synchrotron facility to document the evolution of seed coat thinning from archaeological remains.READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018